CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 259 enrolled
Drug / intervention
Rosuampin 10/5mg +2 moredrug
Likely dose
Rosuampin 10/5mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03951207
NCT03951207Phase 4Completed
CompareCT.gov

Randomized, Multicenter, Parallel, Open, Phase 4 Study to Compare the Efficacy and Safety of Rosuvastatin/Amlodipine Combination Therapy Versus Atorvastatin/Amlodipine Combination Therapy in Hypertension Patient With Dyslipidemia

Yuhan Corporation·interventional·Posted May 15, 2019·Updated Oct 12, 2022

In Brief

A Phase 4 clinical trial evaluating Rosuampin 10/5mg, Rosuampin 20/5mg, and 1 other intervention for Dyslipidemias and Hypertension. Completed, enrolled 259 participants across 1 site.

Detailed Summary

This study is to Compare the Efficacy and Safety of Rosuvastatin/Amlodipine Combination Therapy Versus Atorvastatin/Amlodipine Combination Therapy in Hypertension patient with Dyslipidemia

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDyslipidemias, Hypertension
CountriesSouth Korea
Collaborators--

Timeline

Phase 4CompletedFinished
2020202120222023202420252026
First PostedMay 15, 2019
Enrollment StartMay 30, 2019
Primary CompletionSep 29, 2021
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 7.1 years ago

Interventions

Rosuampin 10/5mgdrug

Rosuvastatin 10mg/Amlodipine 5mg qd for 8 weeks

Rosuampin 20/5mgdrug

Rosuampin 20/5mg qd for 8 weeks

Amlodipine/Atorvastatin 5/20mgdrug

Amlodipine/Atorvastatin 5/20mg qd for 8 weeks